Peter Riedell, MD, is an associate professor of medicine in the Section of Hematology/Oncology at the University of Chicago.

Peter Riedell, MD, assistant professor of medicine, University of Chicago Medicine, discusses the rationale to evaluate survival outcomes after transplant in mantle cell lymphoma (MCL).

MCL is a rare subtype of non-Hodgkin lymphoma in which survival outcomes are heterogenous, Riedell says. For most patients, the standard treatment approach includes intensive induction therapy followed by consolidative autologous stem cell transplant. However, some patients do not derive long-term benefit from this regimen, Riedell explains. 

As such, during the 2021 ASCO Annual Meeting, findings from a study evaluating the effect of time to relapse on overall survival in patients with MCL who underwent this frontline therapeutic approach were presented, Riedell concludes.

Videos

Peter Riedell, MD, discusses the rationale to evaluate survival outcomes after transplant in mantle cell lymphoma.



Dr. Riedell on the Rationale to Evaluate Survival Outcomes After Transplant in MCL 

Peter Riedell, MD, assistant professor of medicine, the University of Chicago Medicine, discusses the importance of identifying early relapse in patients with high-risk mantle cell lymphoma (MCL).

An analysis presented during the 2021 ASCO Annual Meeting examined the effect of time to relapse on overall survival (OS) in patients with MCL following frontline treatment with high-dose therapy and autologous hematopoietic cell transplantation (AHCT). The study concluded that relapse in MCL following AHCT defines a high-risk group with inferior post-relapse OS.

However, limitations of this analysis included the inability to gather information on known risk features of MCL, such as the Ki-67 proliferative index and MCL International Prognostic Index score, according to Riedell. These data would have been helpful in further identifying which patients are more likely to relapse early, as well as in altering treatment strategies to provide greater long-term benefit for this high-risk group, Riedell adds.

Looking forward, these data should be utilized to identify high-risk patients and look for treatment options that would yield greater benefit for them, beyond AHCT, Riedell concludes.

Peter Riedell, MD, discusses the importance of identifying early relapse in patients with high-risk mantle cell lymphoma.

Peter Riedell

Articles

Dr. Riedell on the Rationale to Evaluate Survival Outcomes After Transplant in MCL

Dr. Riedell on the Importance of Identifying Early Relapse High-Risk MCL